InvestorsHub Logo
Post# of 250027
Next 10
Followers 788
Posts 118648
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 239626

Saturday, 03/19/2022 1:37:44 PM

Saturday, March 19, 2022 1:37:44 PM

Post# of 250027
FDA approves BMY’s Opdualag—a_co-formulated_FDC_of Opdivo and anti-LAG-3 relatlimab—in first-line melanoma:

The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232).

In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity.

My abbreviated take:

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.